BR112019021828B1 - Anticorpo anti-pd-l1, molécula de ácido nucleico, célula hospedeira de levedura compreendendo a referida molécula de ácido nucleico, composição compreendendo o anticorpo anti-pdl1 e uso do referido anticorpo para tratar ou prevenir uma doença ou condição associada à modulação da atividade da pd-l1 humana - Google Patents

Anticorpo anti-pd-l1, molécula de ácido nucleico, célula hospedeira de levedura compreendendo a referida molécula de ácido nucleico, composição compreendendo o anticorpo anti-pdl1 e uso do referido anticorpo para tratar ou prevenir uma doença ou condição associada à modulação da atividade da pd-l1 humana Download PDF

Info

Publication number
BR112019021828B1
BR112019021828B1 BR112019021828-9A BR112019021828A BR112019021828B1 BR 112019021828 B1 BR112019021828 B1 BR 112019021828B1 BR 112019021828 A BR112019021828 A BR 112019021828A BR 112019021828 B1 BR112019021828 B1 BR 112019021828B1
Authority
BR
Brazil
Prior art keywords
antibody
seq
cancer
antibodies
cells
Prior art date
Application number
BR112019021828-9A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112019021828A2 (pt
Inventor
Yan Lavrovsky
Ting Xu
Sergei BARBASHOV
Alexey Repik
Mikhail Samsonov
Vasily Ignatiev
Shorena Archuadze
Original Assignee
R-Pharm Overseas, Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by R-Pharm Overseas, Inc filed Critical R-Pharm Overseas, Inc
Publication of BR112019021828A2 publication Critical patent/BR112019021828A2/pt
Publication of BR112019021828B1 publication Critical patent/BR112019021828B1/pt

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
BR112019021828-9A 2017-04-18 2018-04-18 Anticorpo anti-pd-l1, molécula de ácido nucleico, célula hospedeira de levedura compreendendo a referida molécula de ácido nucleico, composição compreendendo o anticorpo anti-pdl1 e uso do referido anticorpo para tratar ou prevenir uma doença ou condição associada à modulação da atividade da pd-l1 humana BR112019021828B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2017028206 2017-04-18
USPCT/US2017/028206 2017-04-18
PCT/US2018/028206 WO2018195226A1 (en) 2017-04-18 2018-04-18 Anti-pd-l1 antibody and use thereof

Publications (2)

Publication Number Publication Date
BR112019021828A2 BR112019021828A2 (pt) 2020-03-24
BR112019021828B1 true BR112019021828B1 (pt) 2022-09-20

Family

ID=63856823

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019021828-9A BR112019021828B1 (pt) 2017-04-18 2018-04-18 Anticorpo anti-pd-l1, molécula de ácido nucleico, célula hospedeira de levedura compreendendo a referida molécula de ácido nucleico, composição compreendendo o anticorpo anti-pdl1 e uso do referido anticorpo para tratar ou prevenir uma doença ou condição associada à modulação da atividade da pd-l1 humana

Country Status (17)

Country Link
US (1) US20210115143A1 (enExample)
EP (1) EP3612565A4 (enExample)
JP (2) JP2020517239A (enExample)
KR (1) KR102323960B1 (enExample)
CN (1) CN110856446A (enExample)
AU (1) AU2018256392B2 (enExample)
BR (1) BR112019021828B1 (enExample)
CA (1) CA3059447A1 (enExample)
CL (1) CL2019002953A1 (enExample)
CO (1) CO2019012118A2 (enExample)
EA (1) EA201900443A1 (enExample)
MA (1) MA50038A (enExample)
MX (1) MX2019012461A (enExample)
MY (1) MY199319A (enExample)
PH (1) PH12019502302A1 (enExample)
SG (1) SG11201909041SA (enExample)
WO (1) WO2018195226A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
JP7497351B2 (ja) * 2018-11-13 2024-06-10 コンパス セラピューティクス リミテッド ライアビリティ カンパニー チェックポイント分子に対する多重特異性結合性構築物およびその使用
CN113646330A (zh) 2018-11-14 2021-11-12 鲁比克治疗股份有限公司 工程化cd25多肽及其用途
CA3120096A1 (en) 2018-11-14 2020-05-22 Rubryc Therapeutics, Inc. Cd25 antibodies
CN109929037B (zh) 2019-04-01 2023-03-17 华博生物医药技术（上海）有限公司 针对程序性死亡配体的结合物及其应用
JP7302010B2 (ja) * 2019-04-11 2023-07-03 スクリップス コリア アンチボディ インスティチュート プログラム細胞死タンパク質リガンド－１（ｐｄ－ｌ１）に対する抗体及びその用途
SG11202103000WA (en) * 2019-04-26 2021-04-29 I Mab Biopharma Us Ltd Human pd-l1 antibodies
US20210403568A1 (en) * 2020-06-29 2021-12-30 Cai Gu Huang Biopharmaceutical formulation of anti-pd-1, anti-pd-l1, and anti-vegfr therapeutic monoclonal antibodies and method for treating nsclc by inhalation
CA3187850A1 (en) 2020-08-04 2022-02-10 Bryan Glaser Pd-l1 binding agents and uses thereof
MX2024001877A (es) 2021-08-10 2024-02-28 Kymab Ltd Tratamiento de dermatitis atopica.
WO2023046113A1 (zh) * 2021-09-24 2023-03-30 广东菲鹏制药股份有限公司 一种抗人pd-l1人源化抗体或其抗原结合片段及其应用
US20240294651A1 (en) 2023-01-30 2024-09-05 Kymab Limited Antibodies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE454137T1 (de) * 2001-07-25 2010-01-15 Facet Biotech Corp Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
MX356367B (es) * 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
US10202454B2 (en) * 2013-10-25 2019-02-12 Dana-Farber Cancer Institute, Inc. Anti-PD-L1 monoclonal antibodies and fragments thereof
WO2015103602A1 (en) * 2014-01-06 2015-07-09 The Trustees Of The University Of Pennsylvania Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
CA3265373A1 (en) * 2014-02-20 2025-10-30 H. Lundbeck A/S Anti-acth antibodies and use thereof
CN105777906B (zh) * 2014-12-19 2019-04-23 苏州丁孚靶点生物技术有限公司 抗pd-l1全人抗体及其应用
MA42971A (fr) * 2015-03-13 2018-08-15 Cytomx Therapeutics Inc Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
JP7011657B2 (ja) * 2016-10-30 2022-02-10 シャンハイ・ヘンリウス・バイオテック・インコーポレイテッド 抗ｐｄ－ｌ１抗体および変異型

Also Published As

Publication number Publication date
CO2019012118A2 (es) 2020-04-01
WO2018195226A1 (en) 2018-10-25
CL2019002953A1 (es) 2020-01-10
US20210115143A1 (en) 2021-04-22
EP3612565A1 (en) 2020-02-26
CA3059447A1 (en) 2018-10-25
SG11201909041SA (en) 2019-11-28
JP2023025003A (ja) 2023-02-21
MY199319A (en) 2023-10-24
EA201900443A1 (ru) 2020-03-06
EP3612565A4 (en) 2021-06-16
PH12019502302A1 (en) 2020-09-21
MX2019012461A (es) 2019-12-11
AU2018256392B2 (en) 2024-05-16
BR112019021828A2 (pt) 2020-03-24
MA50038A (fr) 2020-07-08
KR20190141169A (ko) 2019-12-23
JP2020517239A (ja) 2020-06-18
AU2018256392A1 (en) 2019-10-17
KR102323960B1 (ko) 2021-11-10
CN110856446A (zh) 2020-02-28

Similar Documents

Publication Publication Date Title
KR102323960B1 (ko) 항-pd-l1 항체 및 이의 용도
JP6873445B2 (ja) 抗ガレクチン−９抗体及びその使用
TWI818308B (zh) 標靶ｒｏｒ１的抗體或其抗原結合片段及製備方法和應用
US12509520B2 (en) Anti-CD3 and anti-CD123 bispecific antibody and use thereof
BR112021009835A2 (pt) anticorpo anti-cd40, fragmento de ligação ao antígeno e uso farmacêutico dos mesmos
ES2737307T3 (es) Anticuerpos no antagonistas dirigidos contra la cadena alfa del dominio extracelular del receptor de IL7 y uso del mismo en el tratamiento del cáncer
JP2024534795A (ja) 二重特異性抗体およびその使用
TW202334215A (zh) 靶向cldn18.2之抗體、雙特異性抗體及其應用
TW202438528A (zh) 特異性結合Ｃｌａｕｄｉｎ １８．２的抗體及其製法和應用
KR20230158058A (ko) 시알산-결합 ig-유사 렉틴 15에 특이적인 항체 및 이의 용도
TW202602921A (zh) 多功能ｎｋ細胞接合器
BR112019016513A2 (pt) anticorpo anticâncer conversível de célula t reguladora induzível por ifn-gama (irtca) e usos do mesmo
JP2026507507A (ja) Ｃｃｒ９陽性癌を治療するｃｃｒ９標的化部分
US20240309115A1 (en) Novel multispecific antibodies
JP2024542879A (ja) Ｐｄ－１およびｔｇｆ－ｂｒｉｉ結合ドメインを含む多重特異性結合部位
WO2023019505A1 (zh) 抗TGFβ抗体及其制备方法和应用
EA044327B1 (ru) Антитело к pd-l1 и его применение
HK40082759B (zh) 抗半乳凝素-9抗体及其用途
WO2025241703A1 (zh) 高亲和力b7h7抗体或其抗原结合片段及其用途
HK40105152A (en) Antibodies specific to muc18
WO2023025306A1 (zh) 靶向pd-l1和cldn18.2的双特异性抗体及其制备方法和应用
BR112023019749B1 (pt) Conjugados de exatecano anti-nectina-4, composição farmacêutica que os compreende e seus usos
HK40066347B (en) Cldn18.2-targeting antibody, preparation method thereof, and use thereof
BR122023027661A2 (pt) Proteínas de ligação de tgf-beta-rii
HK40060753B (en) Antibodies specific to muc18

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/04/2018, OBSERVADAS AS CONDICOES LEGAIS

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 8A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2876 DE 18-02-2026 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.